Once I may be close to agree with him, bispecific will eventually overtake CART, as soon as they start moving toward frontline. Restriction/cautions is so far tox managing. Efficacy is already there.
BCMA is so crowded - as are bispecifics for CD20, CD19 etc. Makes a drug like selinexor - which has less activity but a unique MOA - more appealing IMO
Market Data 
Markets 
AI
